On September 16, 2026, the Australian Health Practitioner Regulation Agency (Ahpra) published new guidance for practitioners prescribing off-label, unapproved or compounded medicines, backed by case studies and an explicit warning that the regulator will investigate clinicians with unusual prescribing volumes even absent any complaint. Ahpra said the move follows growing concern about consumer demand for these medicines and, pointedly, "the rise in high-volume and single-treatment business models" — regulator language for the vertically integrated online clinic that sells one category of drug at scale.

Why It Matters

The vertically integrated, single-condition online clinic is the dominant business model in men's sexual health — it is what Hims, Ro, BlueChew and their Australian analogues are. The economics depend on a short intake, a fast prescription, and a house pharmacy; a regulator declaring that a few-minute consultation and undeclared commercial conflict are markers of poor practice is aiming directly at the operating model, not at individual bad actors. Ahpra's precedent is instructive: it says medicinal cannabis units prescribed fell almost 30% after its 2024–25 crackdown, per Department of Health data. That is what a compliance intervention does to volume in a demand-led category. For ED, testosterone and performance-adjacent platforms specifically, the exposure is doubled. Much of the category's growth product — compounded tadalafil troches, unapproved peptides marketed for libido or recovery, TRT via minimal-contact telehealth — sits squarely inside the definition of off-label, unapproved or compounded. The explicit threat of no-complaint investigations triggered by prescribing-pattern analytics means platforms should assume their aggregate scripts are already visible to the regulator. And the pattern is global: this lands in the same month that the US FTC's privacy-and-billing case against Hims & Hers spawned a securities class action and a Florida consumer suit. Two different regulators on two continents are converging on the same conclusion — that the frictionless intake funnel is the product, and the product is the problem.

The guidance's first principle is blunt. "Patient demand alone is not a valid reason to prescribe a medicine," it reads. "Off-label, unapproved, or compounded medicines should only be prescribed when there is sufficient evidence, a clear clinical indication or when other treatments have not worked or are inappropriate for the patient." Ahpra lists specific markers of poor practice: prescribing without a legitimate indication, consultations lasting a few minutes or less, failing to check real-time prescription monitoring before prescribing, and failing to adequately declare a conflict of interest. Subsequent sections cover informed consent — patients must understand the medicine is unapproved for the intended use and has not been assessed by the TGA for safety, efficacy and quality — and documentation of risk-benefit reasoning and continuity of care.

Medical Board of Australia Chair Dr Susan O'Dwyer tied it to existing obligations rather than new ones. "Existing professional and legal obligations apply to practitioners who are active in these new pharmaceutical frontiers," she said. "Peptides are like other drugs: a patient may want peptides, but that doesn't mean they need peptides. It doesn't mean that peptides are clinically justified." Ahpra CEO Justin Untersteiner warned Australians off black-market peptides and online influencers with "zero clinical knowledge or training," adding that the regulator does not need to wait for a notification: "If we see red flags, such as unusual prescribing patterns or inappropriate advertising, we can take it up with the practitioner directly or notify other agencies where businesses are involved." TGA head Professor Anthony Lawler said the guidance would "help practitioners make informed prescribing decisions."

The timing is not coincidental. The TGA confirmed this week that a patient tore their oesophagus after uncontrolled vomiting caused by a counterfeit weight-loss peptide. And a week earlier, independent MP Dr Monique Ryan — a paediatric neurologist — wrote to health minister Mark Butler calling for an inquiry into Australian telehealth, telling The Medical Republic that Ahpra, the TGA and the ACCC lack sufficient oversight of vertically integrated telehealth companies with commercial relationships to medication wholesalers. "When vertically integrated companies with in-house pharmacists have existing commercial relationships with pharmaceutical companies, it's in their best interests to prescribe and dispense drugs to patients," Ryan said, calling the current situation "a regulatory desert." RACGP President Dr Michael Wright welcomed the guidance, describing much of this prescribing as happening in "a no man's land of regulation" outside Medicare and the PBS. Ahpra says conflict-of-interest guidance and patient-facing telehealth information are coming next.

Sources

Update — 2026-09-16

Initial entry — story first created.